Archives: Speakers

I am a M.Sc. graduate in life sciences and Bbiotechnology (the Hebrew University of Jerusalem, Israel). After graduating’ I have acquired vast experience in the biomed industry and research and development of innovative botanical products. For the past six years, I have served as R&D, Quality and Vocational Training Director in the Israeli Ministry of Health’s Medical Cannabis Agency (IMCA). There, I took a major part in designing the policy and regulation for the emerging medical cannabis industry, including writing the clinical methodology and quality procedures for medical cannabis products. Currently, I am the Head of the Medical Cannabis Clinical Research Center at the Chaim Sheba Hospital, Tel Hashomer, Israel; and an academic coordinator of the “cannabis for medical and research” course in the School of Graduate Studies, Sackler Faculty of Medicine, Tel Aviv University.

Julio discovered he had Hepatitis C by chance in 1994. He went through three year-long courses on interferon treatment. These years were not easy and Julio struggled with many challenges and questions and he looked for support. When he realized there are no support groups or patient associations for liver patients in Israel, Julio decided in 1998 to establish Hetz- the Israeli Organization for Liver Health. Today Julio is cured from HCV. Nevertheless, he dedicates his life to supporting liver patients and their families, strengthening Hetz’s capacity to advocate for the PATIENTS’ RIGHT TO KNOW they have a liver disease, and the government’s obligation to screen and to treat them. Actually Julio is directing HETZ and is representative of the patients in the National Council of Liver of the Ministry of Health in Israel.

Yael Genosar, Associate Director of Clinical Supply Chain at OPKO Biologics Israel. Experienced Clinical Supply chain manager with four years of experience in managing supply chain in a global clinical trial. Previously Project Manager at Hot Mobile a wireless telecommunications company, leading technologies projects.

Ms. Xia currently holds the position of Head of Supply Chain at Agios Pharmaceutical located in Cambridge, Massachusetts. Her responsibility includes clinical supplies, commercial supplies, logistic/commercial distribution and supply chain planning. Wendy is a chemist by training and has spent her early years in Chemical Development as a process chemist and analytical chemist. She then spent 20 years in Quality and Supply Chain organizations in major pharmaceutical companies in New Jersey before relocating to Cambridge, Massachusetts joining Agios in 2014. In 7 years, Wendy has successfully built a complete supply chain organization supporting clinical and commercial portfolios.

Seasoned R&D Industry professional with over 30 years of experience in large pharma, mid-sized, start-up and virtual settings. Career appointments span the full spectrum of product life-cycle management, across every phase of development and every research platform, including pharmaceuticals, biologics, devices, combination products, gene and stem cell therapeutics, Phases I-IV. Achievements include contribution to the US and International market approval of 6 biopharmaceutical products.

Scott Sutton is the Senior Director, Supply Chain for MorphoSys in Boston, MA. He has 20 years of experience managing both clinical and commercial supply chains across a wide variety of drugs and therapeutic areas, with an emphasis in oncology and rare disease. Scott’s supply chain experience ranges across Phase I to Phase IV clinical trials, commercial product launches, global supply management, vendor sourcing, international logistics, and sales & operations planning management.

Mr. Bennett has worked in clinical development for approximately 20 years and has worked for WCT since September 2021. He began his career in clinical research in a phase 1 clinic and soon after held roles as a Clinical Research Associate on both early and late phase clinical trials with responsibilities for data validation and site management. This solid base experience in ICH-GCP was further supplemented with broad operational knowledge regarding the conduct of clinical trials when he was appointed as a Clinical Trial Manager of Phase I, II and II trials within global programs. Building on this operational grounding, he has latterly (seven years) held positions where he has led crossfunctional project teams within clinical research and has been responsible for project strategies, clinical development plans, clinical trial methodologies (concept/design), protocol authorship and the transformation of the scientific endeavor into an operationalized activity. Through being part of R&D leadership teams, he has contributed to business management and the development of operating models and outsourcing strategies. He has been responsible for representing pipeline projects in R&D governance boards and holds experiences throughout the drug development life cycle.